February 19, 2025: Washington, DC – The National Consumers League (NCL) opposes the Trump Administration’s firing of public servants working at the National Highway Traffic Safety Administration (NHTSA), the nation’s principal automobile safety regulator. According to reports, the Trump Administration fired hundreds of people at the Department of Transportation, including employees at NHTSA.
February 14, 2025: Washington, DC – The National Consumers League (NCL) is alarmed by the recent mass firings of probationary federal employees in the name of “government efficiency and cutting waste.” These dedicated public servants – unsung heroes – provide essential services that consumers rely on. Their dismissal threatens the well-being of millions of Americans.
February 13, 2025: Washington, DC – The National Consumers League (NCL), a long-time advocate for consumer health and safety, is disappointed with the Senate’s confirmation of Robert F. Kennedy Jr. as Secretary of Health and Human Services (HHS), which oversees agencies such as the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH). NCL has consistently supported science, evidence-based medicine, and public health and believes this appointment poses a significant risk to Americans’ health and well-being. Kennedy, who holds a law degree and has no medical training, is uniquely unqualified for this role.
February 12, 2025: Washington, DC – Today, House Republicans released a budget resolution, which guides federal spending and revenue policies and initiates the reconciliation process. The resolution calls for at least $1.5 trillion in spending reductions and $4.5 trillion in tax cuts. The accompanying “budget blueprint” lays out a series of proposals that would eliminate core manufacturing and clean energy policies established in the Inflation Reduction Act and severely weakens Medicaid, which provides health insurance for nearly 72 million Americans.
February 12, 2025: Washington, DC – The National Consumer League (NCL) reiterates its strong support for the Federal Trade Commission’s (FTC) noncompete rule. This week, the AHA and Federation of American Hospitals filed a friend-of-the-court brief in the U.S. Court of Appeals for the 5th Circuit urging the court to vacate the Federal Trade Commission’s noncompete rule nationwide. NCL disagrees with this effort to do away with this crucial regulation, ensuring that workers, regardless of industry, are free to pursue better opportunities without being held back by restrictive clauses that unfairly limit their mobility.
February 12, 2025: One of the dates seared into my memory from a young age is February 12 —President Abraham Lincoln’s birthday. We’ve had some truly heroic presidents, but it’s hard to compare any to the towering figure of Abraham Lincoln.
February 12, 2025: Washington, DC – The National Consumers League (NCL) is raising serious concerns over recent lobbying efforts by the Meat Institute, which is urging the Trump administration to roll back essential regulations designed to protect workers, the environment, and consumers in the meatpacking and factory farm industries. NCL’s concerns are heightened by disturbing reports of widespread hazardous child labor in the industry, including children working night shifts to clean factories with caustic chemicals.
February 11, 2025: Washington, DC – Yesterday, the National Consumers League (NCL) and four other public interest organizations filed comments with the U.S. Department of Transportation (DOT) urging the Department to implement passenger protections in the event of significant flight delays and cancellations. Under federal law enacted last year, DOT must act on the issue by May 16.
February 7, 2025: Washington, DC – The National Consumers League (NCL) is deeply concerned about the Trump administration’s recent announcement of new tariffs on imports from Canada, Mexico, and China. NCL is fearful that this decision could significantly impact American consumers, affecting a wide range of goods that are integral to daily life.
February 5, 2025: Washington, DC – Today, the National Consumers League (NCL) joined over 25 patient and provider advocacy organizations in voicing strong opposition to the proposed expansion of the 340B Drug Pricing Program under NY Senate Bill 1913.
The work of the National Consumers League is making a difference in people’s lives across the country. Meet some of the consumers touched by our programs.
Read about NCL’s impact
Paige, 55, a Nashville wife and mother of two, answered an employment ad for secret shoppers. Before sending payment to the scammers, she reached out to NCL.
Read about NCL’s impact
A grease fire flared up in Decklan’s kitchen. As his family scrambled and panicked, fearing that the whole house might erupt in flames, Decklan remained calm. He hurried over to the pantry, grabbed some baking soda, and dumped it on the fire quickly extinguishing the blaze.
Read about NCL’s impact
Cincinnati resident Charles, 45, lost his computer business — and health insurance— during a time of economic downturn. A diabetic, Charles was now unable to afford his medication. He stopped taking it which made him seriously ill and put his life at risk.
Read about NCL’s impact
Jeremy is a fast-food worker who has been employed at a number of Chipotle restaurants in New York City. When he was just 20 years old, he took part in an NCL research project that revealed that management practices within the fast food chain were putting workers—and food safety for customers—at risk.
Read about NCL’s impact
By Sally Greenberg, NCL Executive Director
While the COVID-19 pandemic has led to hardship for all Americans, it is clear that people of color have been disproportionately burdened. Across the health care continuum, addressing this disparity has become part of the broader conversation about the history of systemic racism and the underlying social determinants of health that negatively affect the mental, physical, and economic health of individuals and entire communities.
The pandemic has underscored persistent health disparities, and there is growing recognition that representation in research and clinical trials can have a profound impact on health outcomes. A lack of representation from racially and ethnically diverse groups in research and clinical trials have typically led to gaps in data, missing the opportunity to assess the full impact of various treatments and drugs across a range of populations. The collection and use of real-world research and data to inform the potential use, risks, and benefits of medical products and treatments can ultimately lead to better health outcomes, particularly for those who have been underrepresented in the past.
Existing efforts to improve inclusion
Efforts to expand diversity and representation in medical research are underway in Congress. Policymakers are encouraging the incorporation of Real World Evidence (RWE) in drug development through the recent Cures 2.0 draft legislation released by Reps. Diana Degette (D-CO-1) and Fred Upton (D-MI-6). While the status quo limits us from effectively reaching underserved populations, the proposed legislation would allow studies that include RWE for some drugs after they have been approved. At the heart of this issue is a growing appreciation that the same therapy can affect different populations in different ways, which is why Cures 2.0 supports collecting data that more accurately reflects the unique experiences and needs of patients across diverse populations.
Recognizing the potential for RWE in maternal health
The lack of representative research in the field of maternal health is undeniable, and its implications are staggering. The dismal state of maternal care in the United States reflects how our health care system has failed women of color, including by not adequately studying treatment options to prevent maternal morbidity and mortality. The need for RWE is clear when you consider the persistent disparities in health outcomes that plague minority communities.
Preterm birth and its disproportionate impact on women of color is a stark illustration of the need to make progress on representative research in maternal health. Preterm birth is the second-largest contributor to infant death in America today. Despite the tremendous physical, emotional, and financial toll that preterm birth continues to take on our country — disproportionately so on women and families of color — not enough therapeutic tools currently exist to prevent it.
Today, “17P,” the only FDA-approved treatment to help reduce the likelihood of spontaneous, recurrent preterm birth in the United States is at-risk of being withdrawn from the market in all its forms, including the branded product and five generic versions. Unfortunately there is conflicting evidence from two different clinical trials, one representative of a diverse U.S. population and another studied in a largely white population in Europe. It’s not a straightforward comparison. If 17P is withdrawn, the women most affected by preterm birth, predominantly women of color, would be left without an FDA-approved treatment option.
The FDA is considering the path forward, including additional data collection through leveraging RWE from past patient use. The success of the first (approval) trial for 17P in the impacted communities signals the importance of RWE. Continued access to 17P is, at its core, a matter of health equity. Black women must not yet again be left vulnerable to a system that historically has overlooked them.
